Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 262 results for "dr reddy"

Dr. Reddy's Laboratories to consider dividend

First Published: Thu, April 12 2018. 11:56 IST RECOMMENDED FOR YOU RECOMMENDED FOR YOU Business Standard, 1 week ago

96 images for dr reddy

DNA, 1 week ago
Business Standard, 2 weeks ago
Business Standard, 3 weeks ago
Business Standard, 3 weeks ago
Money Control, 5 days ago
Business Standard, 1 month ago
Mathrubhumi, 3 weeks ago
Business Standard, 1 month ago
Money Control, 3 weeks ago
Money Control, 3 weeks ago
Money Control

Indian ADRs: Wipro, ICICI Bank, Dr Reddy#39;s Lab gain

Indian ADRs ended mostly higher on Monday. ICICI Bank gained 1.54 percent and Dr Reddy#39;s Laboratories advanced 1.11 percent.
 Money Control1 week ago Indian ADRs: Infosys, Dr Reddy#39;s Lab, HDFC Bank down 2%  Money Control2 weeks ago Indian ADRs: ICICI Bank slips 7%; Infosys, Dr Reddy#39;s Lab down  Money Control2 weeks ago Dr Reddy#39;s ropes in ex-Teva executive to run operations  Money Control3 weeks ago
[x]  

Yadgir BJP ticket aspirant's car bursts into flames

BJP ticket aspirant from Yadagir Dr Sharanabhoopala Reddys car suddenly burst into flames, while the vehicle was still in motion. Astonishingly, Reddy who was seated inside the car escaped unhurt. The incident occurred at Ibrahimpura Cross in Yadagir ...
 Deccan Herald1 week ago
Business Standard

Erez Israeli to join Dr. Reddy's Laboratories as COO

Dr. Reddy's Laboratories Ltd. today announced the appointment of Erez Israeli, former President and CEO of Enzymotec, as the Chief Operating Officer (COO), succeeding Abhijit Mukherjee, who will retire on March 31 after a 15-year career with the ...
 Business Standard3 weeks ago Dr Reddy's appoints Erez Israeli as head of generics biz  Business Standard3 weeks ago Dr Reddy's names ex-Teva official Erez Israeli as COO, global generics head  Business Standard3 weeks ago Dr Reddy's appoint Erez Israeli as COO  Business Standard3 weeks ago
[x]  
Business Standard

Dr Reddy's launches generic nausea drug in US

Dr Reddy's Laboratories today said it has launched Palonosetron Hydrochloride Injection, used in treating acute nausea and vomiting, in the US market.The Hyderabad-based firm launched the product after getting approval from the US Food and Drug Administration ...
 Business Standard3 weeks ago Dr Reddy's launches anti-nausea injection for cancer patients in US  Business Standard3 weeks ago Dr Reddy’s Laboratories gains 2% on Tetrabenazine tablets launch in US market  Money Control2 months ago Dr Reddy's launches generic Tetrabenazine tablets in US  Business Standard2 months ago
Business Standard

Dr Reddy's enters $ 71 mn market with launch of anti-allergy drug in US

BS ReporterHyderabad, 16 March: Dr Reddy's Laboratories Limited announced today that it has launched Levocetrizine Dihydrochloride tablets, an over-the counter(OTC) therapeutic equivalent generic version of Xyzal Allergy tablets in the US market as approved ...
 Business Standard1 month ago Dr Reddy's launches allergy relief tablets in US  Business Standard1 month ago Dr Reddy#39;s launches allergy relief tablets in US  Money Control1 month ago Dr Reddy#39;s may face delays in launch of gSuboxone as Indivior throws new patent challenge  Money Control2 months ago
Business Standard

Dr Reddy's drops after maintaining OAI status for facility

after the company said that the US drug regulator has maintained official action indicated status for its active pharmaceutical ingredient manufacturing plant. The announcement was made on Sunday, 25 February 2018. Meanwhile, the S BSE Sensex was up 217.16 ...
 Business Standard1 month ago Aster DM Healthcare in focus on debut  Business Standard1 month ago Dr Reddy's gets EIR, says USFDA maintained OAI status for Srikakulam plant  Business Standard1 month ago
Business Standard

Dr. Reddy's files NDA for migraine candidate

Pharma major Dr. Reddy's Laboratories Ltd and its American subsidiary, Promius Pharma, LLC on Monday announced the filing of a New Drug Application (NDA) for its migraine candidate DFN-02 with the US Food and Drug Administration (USFDA).According to Anil ...
 Prokerala2 weeks ago Dr Reddy's files new drug application for migraine spray with USFDA  Business Standard2 weeks ago
Money Today

Closing Bell: Sensex ends on a flat note, Nifty below 10,400; midcaps take a hit

Sun Pharma, Adani Ports, and Aurobindo Pharma were the top gainers, while Dr Reddy’s Labs, ONGC and BPCL lost the most.
 Money Control1 month ago Sensex rises 441 points, Nifty at 10,599; Sun Pharma, Dr Reddy's, Infosys top gainers  Money Today2 months ago Closing Bell: Sensex ends over 60 pts lower ahead of Budget, Nifty holds 11K  Money Control2 months ago Tech stocks propel Sensex past 34K mark  Rediff.com1 week ago
[x]  
Rediff.com

Why Dr Reddy's expects FY19 to be stronger and richer

The US drug regulator raised the issue of significant deviations from the current good manufacturing practice (cGMP) in three of DRRD's plants in a letter issued in November 2015   Investors in Dr Reddy's Laboratories got a shock when the drug firm received an establishment inspection report from the US Food and Drug Administration (FDA) that maintained OAI (official action initiated) status for its API (active pharma ingredient) facility at Srikakulam in Andhra Pradesh.   The ...
 Rediff.com1 month ago Dr Reddy's is awaiting 102 approvals from US Food and Drug Administration  Business Standard1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less